Prefilled syringes for intravitreal drug delivery

Thérèse M Sassalos,1 Yannis M Paulus1,2 1Department of Ophthalmology and Visual Sciences, W.K. Kellogg Eye Center, University of Michigan, Ann Arbor, MI, USA; 2Department of Biomedical Engineering, University of Michigan, Ann Arbor, MI, USA Abstract: Intravitreal injections o...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Sassalos TM, Paulus YM
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2019
Materias:	diabetic retinopathy anti-VEGF intravitreal injection intravitreous injection ranibizumab prefilled syringe Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/99a2a6b7448049faa3047db700037d5e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:99a2a6b7448049faa3047db700037d5e
record_format	dspace
spelling	oai:doaj.org-article:99a2a6b7448049faa3047db700037d5e2021-12-02T06:01:59ZPrefilled syringes for intravitreal drug delivery1177-5483https://doaj.org/article/99a2a6b7448049faa3047db700037d5e2019-04-01T00:00:00Zhttps://www.dovepress.com/prefilled-syringes-for-intravitreal-drug-delivery-peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483Thérèse M Sassalos,1 Yannis M Paulus1,2 1Department of Ophthalmology and Visual Sciences, W.K. Kellogg Eye Center, University of Michigan, Ann Arbor, MI, USA; 2Department of Biomedical Engineering, University of Michigan, Ann Arbor, MI, USA Abstract: Intravitreal injections of anti-vascular endothelial growth factor (VEGF) medications play an increasingly critical role in numerous retinal vascular diseases. Initially, anti-VEGF medications came in vials that had to be drawn up by the physician into a syringe for administration. In 2018, the US Food and Drug Administration (US FDA) approved the ranibizumab 0.3 mg prefilled syringe (PFS), and in October 2016, the US FDA approved the ranibizumab 0.5 mg PFS. This article discusses the advantages of the PFS, including reduced injection time, possible reduced risk of endophthalmitis, reduction in intraocular air bubbles and silicone oil droplets, and improved precision in the volume and dose of intravitreal ranibizumab administered, along with possible disadvantages. Implications of the innovation of the PFS on intravitreal injection technique and clinical practice pattern are discussed and reviewed. Keywords: intravitreal injection, intravitreous injection, anti-VEGF, ranibizumab, prefilled syringe, diabetic retinopathySassalos TMPaulus YMDove Medical Pressarticlediabetic retinopathyanti-VEGFintravitreal injectionintravitreous injectionranibizumabprefilled syringeOphthalmologyRE1-994ENClinical Ophthalmology, Vol Volume 13, Pp 701-706 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	diabetic retinopathy anti-VEGF intravitreal injection intravitreous injection ranibizumab prefilled syringe Ophthalmology RE1-994
spellingShingle	diabetic retinopathy anti-VEGF intravitreal injection intravitreous injection ranibizumab prefilled syringe Ophthalmology RE1-994 Sassalos TM Paulus YM Prefilled syringes for intravitreal drug delivery
description	Thérèse M Sassalos,1 Yannis M Paulus1,2 1Department of Ophthalmology and Visual Sciences, W.K. Kellogg Eye Center, University of Michigan, Ann Arbor, MI, USA; 2Department of Biomedical Engineering, University of Michigan, Ann Arbor, MI, USA Abstract: Intravitreal injections of anti-vascular endothelial growth factor (VEGF) medications play an increasingly critical role in numerous retinal vascular diseases. Initially, anti-VEGF medications came in vials that had to be drawn up by the physician into a syringe for administration. In 2018, the US Food and Drug Administration (US FDA) approved the ranibizumab 0.3 mg prefilled syringe (PFS), and in October 2016, the US FDA approved the ranibizumab 0.5 mg PFS. This article discusses the advantages of the PFS, including reduced injection time, possible reduced risk of endophthalmitis, reduction in intraocular air bubbles and silicone oil droplets, and improved precision in the volume and dose of intravitreal ranibizumab administered, along with possible disadvantages. Implications of the innovation of the PFS on intravitreal injection technique and clinical practice pattern are discussed and reviewed. Keywords: intravitreal injection, intravitreous injection, anti-VEGF, ranibizumab, prefilled syringe, diabetic retinopathy
format	article
author	Sassalos TM Paulus YM
author_facet	Sassalos TM Paulus YM
author_sort	Sassalos TM
title	Prefilled syringes for intravitreal drug delivery
title_short	Prefilled syringes for intravitreal drug delivery
title_full	Prefilled syringes for intravitreal drug delivery
title_fullStr	Prefilled syringes for intravitreal drug delivery
title_full_unstemmed	Prefilled syringes for intravitreal drug delivery
title_sort	prefilled syringes for intravitreal drug delivery
publisher	Dove Medical Press
publishDate	2019
url	https://doaj.org/article/99a2a6b7448049faa3047db700037d5e
work_keys_str_mv	AT sassalostm prefilledsyringesforintravitrealdrugdelivery AT paulusym prefilledsyringesforintravitrealdrugdelivery
_version_	1718400123713617920

Prefilled syringes for intravitreal drug delivery

Ejemplares similares